As promised, President Trump has promptly abandoned the Trans-Pacific Partnership. What might this mean for biopharma?
Nixing the so-called TPP could spell trouble for the biopharmaceutical industry moving forward when it comes to market exclusivity, according to Kevin Noonan, a partner at Chicago-based intellectual property law firm McDonnell Boehnen Hulbert & Berghoff.
The TPP, though not approved yet by Congress, had been President Obama’s hallmark trade deal. It was an ambitious bipartisan plan meant to expand trade in the Pacific Rim, allowing countries other than China to gain ground in international commerce.
About the Author Reprints
